[144] Hims & Hers Health, Inc. SEC Filing
Hims & Hers Health, Inc. (HIMS) 鈥� Form 144 filing discloses an insider鈥檚 intention to sell 250 Class A shares (estimated market value $16,110) on or after 1 Aug 2025 through Fidelity Brokerage on the NYSE. The notice also details recent insider activity: over the past three months the same individual, Michael Y. Chi, has already sold 69,802 Class A shares for gross proceeds of 鈮�$4.27 million. Outstanding Class A shares total 215.45 million, so the planned sale represents a negligible 0.0001% of shares outstanding, while the cumulative three-month sales equal roughly 0.03%.
The signer affirms he is unaware of any undisclosed material adverse information and, if relying on Rule 10b5-1, that a compliant trading plan exists. No other financial metrics, guidance, or operational updates are provided; the filing is strictly a procedural notice under Rule 144.
Hims & Hers Health, Inc. (HIMS) 鈥� Comunicazione ai sensi del Modulo 144 rivela l'intenzione di un insider di vendere 250 azioni di Classe A (valore di mercato stimato $16.110) a partire dal 1 agosto 2025 tramite Fidelity Brokerage alla NYSE. La notifica dettaglia inoltre le recenti operazioni dell'insider: negli ultimi tre mesi la stessa persona, Michael Y. Chi, ha gi脿 venduto 69.802 azioni di Classe A per un ricavo lordo di circa $4,27 milioni. Le azioni di Classe A in circolazione sono complessivamente 215,45 milioni, quindi la vendita prevista rappresenta una quota trascurabile dello 0,0001% del totale, mentre le vendite cumulative degli ultimi tre mesi ammontano a circa lo 0,03%.
Il firmatario dichiara di non essere a conoscenza di alcuna informazione materiale negativa non divulgata e, se si basa sulla Regola 10b5-1, che esiste un piano di trading conforme. Non vengono forniti altri dati finanziari, previsioni o aggiornamenti operativi; la comunicazione 猫 esclusivamente una notifica procedurale ai sensi della Regola 144.
Hims & Hers Health, Inc. (HIMS) 鈥� Presentaci贸n del Formulario 144 revela la intenci贸n de un insider de vender 250 acciones Clase A (valor de mercado estimado de $16,110) a partir del 1 de agosto de 2025 a trav茅s de Fidelity Brokerage en la NYSE. La notificaci贸n tambi茅n detalla la actividad reciente del insider: en los 煤ltimos tres meses, la misma persona, Michael Y. Chi, ya ha vendido 69,802 acciones Clase A por ingresos brutos de aproximadamente $4.27 millones. El total de acciones Clase A en circulaci贸n es de 215.45 millones, por lo que la venta planeada representa un porcentaje insignificante del 0.0001% del total, mientras que las ventas acumuladas en tres meses suman alrededor del 0.03%.
El firmante afirma no tener conocimiento de informaci贸n material adversa no divulgada y, si se basa en la Regla 10b5-1, que existe un plan de trading conforme. No se proporcionan otros datos financieros, pron贸sticos ni actualizaciones operativas; la presentaci贸n es estrictamente un aviso procedimental bajo la Regla 144.
Hims & Hers Health, Inc. (HIMS) 鈥� Form 144 鞝滌稖鞚� 雮措秬鞛愱皜 250欤� 韥措灅鞀� A 欤检嫕(鞁滌灔 臧�旃� 鞎� $16,110)鞚� 2025雲� 8鞗� 1鞚� 鞚错泟 NYSE鞚� Fidelity Brokerage毳� 韱淀暣 毵る弰頃� 鞚橂弰毳� 瓿店皽頃╇媹雼�. 瓿奠鞐愲姅 斓滉芳 雮措秬鞛� 瓯半灅 雮挫棴霃� 韽暔霅橃柎 鞛堧姅雿�, 霃欖澕 鞚鸽鞚� Michael Y. Chi臧� 歆�雮� 3臧滌洈 霃欖晥 鞚措 69,802欤� 韥措灅鞀� A 欤检嫕鞚� 毵る弰頃橃棳 齑� 鞎� $427毵�鞚� 靾橃澋鞚� 鞓牳鞀惦媹雼�. 氚滍枆霅� 韥措灅鞀� A 欤检嫕鞚� 齑� 2鞏� 1,545毵� 欤�搿�, 瓿勴殟霅� 毵る弰電� 鞝勳泊 欤检嫕鞚� 氙鸽頃� 0.0001%鞐� 頃措嫻頃橂┌, 3臧滌洈 雸勳爜 毵る弰電� 鞎� 0.03%鞐� 雼暕雼堧嫟.
靹滊獏鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵�鞝曥爜 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頃橂┌, Rule 10b5-1鞐� 霐半澕 瓯半灅 瓿勴殟鞚� 欷�靾橂悩瓿� 鞛堨潓鞚� 氚濏灆雼堧嫟. 雼るジ 鞛 歆�響�, 鞝勲, 鞖挫榿 鞐呺嵃鞚错姼電� 鞝滉车霅橃 鞎婌晿鞙茧┌, 鞚措矆 鞝滌稖鞚� Rule 144鞐� 霐半ジ 鞝堨皑鞝� 瓿奠鞐� 攵堦臣頃╇媹雼�.
Hims & Hers Health, Inc. (HIMS) 鈥� D茅p么t du formulaire 144 r茅v猫le l鈥檌ntention d鈥檜n initi茅 de vendre 250 actions de Classe A (valeur marchande estim茅e 脿 16 110 $) 脿 partir du 1er ao没t 2025 via Fidelity Brokerage 脿 la NYSE. L鈥檃vis d茅taille 茅galement les activit茅s r茅centes de l鈥檌niti茅 : au cours des trois derniers mois, la m锚me personne, Michael Y. Chi, a d茅j脿 vendu 69 802 actions de Classe A pour un produit brut d鈥檈nviron 4,27 millions de $. Le nombre total d鈥檃ctions de Classe A en circulation est de 215,45 millions, ainsi la vente pr茅vue repr茅sente une part n茅gligeable de 0,0001 % des actions en circulation, tandis que les ventes cumul茅es sur trois mois s鈥櫭﹍猫vent 脿 environ 0,03 %.
Le signataire affirme ne pas avoir connaissance d鈥檌nformations d茅favorables non divulgu茅es et, s鈥檌l s鈥檃ppuie sur la r猫gle 10b5-1, qu鈥檜n plan de trading conforme est en place. Aucune autre donn茅e financi猫re, pr茅vision ou mise 脿 jour op茅rationnelle n鈥檈st fournie ; ce d茅p么t est strictement un avis proc茅dural conform茅ment 脿 la r猫gle 144.
Hims & Hers Health, Inc. (HIMS) 鈥� Form 144 Einreichung offenbart die Absicht eines Insiders, 250 Class A Aktien (gesch盲tzter Marktwert $16.110) ab dem 1. August 2025 眉ber Fidelity Brokerage an der NYSE zu verkaufen. Die Mitteilung enth盲lt zudem Details zu j眉ngsten Insideraktivit盲ten: In den vergangenen drei Monaten hat dieselbe Person, Michael Y. Chi, bereits 69.802 Class A Aktien verkauft und dabei Bruttoerl枚se von rund $4,27 Millionen erzielt. Die ausstehenden Class A Aktien belaufen sich auf insgesamt 215,45 Millionen, sodass der geplante Verkauf einen vernachl盲ssigbaren Anteil von 0,0001% der ausstehenden Aktien darstellt, w盲hrend die kumulierten Verk盲ufe der letzten drei Monate etwa 0,03% ausmachen.
Der Unterzeichner best盲tigt, dass ihm keine nicht offengelegten wesentlichen negativen Informationen bekannt sind und dass im Falle der Nutzung der Regel 10b5-1 ein konformer Handelsplan besteht. Es werden keine weiteren finanziellen Kennzahlen, Prognosen oder operative Updates bereitgestellt; die Einreichung ist ausschlie脽lich eine formale Mitteilung gem盲脽 Regel 144.
- Sale size is de minimis: 250 shares represent only 0.0001% of the 215.45 m shares outstanding.
- Compliance affirmation: Insider certifies no undisclosed material adverse information, indicating adherence to Rule 144 and governance best practices.
- Ongoing insider selling: 69,802 shares (~$4.27 m) liquidated over the last three months could dampen investor sentiment.
- Signal risk: Repeated disposals may be interpreted as reduced insider confidence despite immaterial absolute size.
Insights
TL;DR: Small additional sale; pattern of insider disposals ~0.03% of float, sentiment slightly negative but immaterial to fundamentals.
The Form 144 signals another minor divestiture by Michael Y. Chi. Although the current 250-share lot is trivial, the aggregate 69.8 k shares sold since June generated ~$4.3 m. Relative to the 215 m share float, this activity is immaterial and unlikely to affect liquidity or ownership structure. Still, repeated insider selling can pressure sentiment, particularly for growth names where perception of executive conviction matters. No operational data accompanies the filing, so valuation drivers remain unchanged.
TL;DR: Filing satisfies Rule 144 disclosure; insider certifies no undisclosed adverse info 鈥� governance risk low.
Rule 144 requires insiders to pre-notify the market of intended sales. The certification that the insider knows of no material non-public negatives鈥攁nd possible reliance on a 10b5-1 plan鈥攔educes litigation and governance risk. The modest size relative to float suggests no control implications. However, continued sales create optics of reduced insider alignment that investors may monitor.
Hims & Hers Health, Inc. (HIMS) 鈥� Comunicazione ai sensi del Modulo 144 rivela l'intenzione di un insider di vendere 250 azioni di Classe A (valore di mercato stimato $16.110) a partire dal 1 agosto 2025 tramite Fidelity Brokerage alla NYSE. La notifica dettaglia inoltre le recenti operazioni dell'insider: negli ultimi tre mesi la stessa persona, Michael Y. Chi, ha gi脿 venduto 69.802 azioni di Classe A per un ricavo lordo di circa $4,27 milioni. Le azioni di Classe A in circolazione sono complessivamente 215,45 milioni, quindi la vendita prevista rappresenta una quota trascurabile dello 0,0001% del totale, mentre le vendite cumulative degli ultimi tre mesi ammontano a circa lo 0,03%.
Il firmatario dichiara di non essere a conoscenza di alcuna informazione materiale negativa non divulgata e, se si basa sulla Regola 10b5-1, che esiste un piano di trading conforme. Non vengono forniti altri dati finanziari, previsioni o aggiornamenti operativi; la comunicazione 猫 esclusivamente una notifica procedurale ai sensi della Regola 144.
Hims & Hers Health, Inc. (HIMS) 鈥� Presentaci贸n del Formulario 144 revela la intenci贸n de un insider de vender 250 acciones Clase A (valor de mercado estimado de $16,110) a partir del 1 de agosto de 2025 a trav茅s de Fidelity Brokerage en la NYSE. La notificaci贸n tambi茅n detalla la actividad reciente del insider: en los 煤ltimos tres meses, la misma persona, Michael Y. Chi, ya ha vendido 69,802 acciones Clase A por ingresos brutos de aproximadamente $4.27 millones. El total de acciones Clase A en circulaci贸n es de 215.45 millones, por lo que la venta planeada representa un porcentaje insignificante del 0.0001% del total, mientras que las ventas acumuladas en tres meses suman alrededor del 0.03%.
El firmante afirma no tener conocimiento de informaci贸n material adversa no divulgada y, si se basa en la Regla 10b5-1, que existe un plan de trading conforme. No se proporcionan otros datos financieros, pron贸sticos ni actualizaciones operativas; la presentaci贸n es estrictamente un aviso procedimental bajo la Regla 144.
Hims & Hers Health, Inc. (HIMS) 鈥� Form 144 鞝滌稖鞚� 雮措秬鞛愱皜 250欤� 韥措灅鞀� A 欤检嫕(鞁滌灔 臧�旃� 鞎� $16,110)鞚� 2025雲� 8鞗� 1鞚� 鞚错泟 NYSE鞚� Fidelity Brokerage毳� 韱淀暣 毵る弰頃� 鞚橂弰毳� 瓿店皽頃╇媹雼�. 瓿奠鞐愲姅 斓滉芳 雮措秬鞛� 瓯半灅 雮挫棴霃� 韽暔霅橃柎 鞛堧姅雿�, 霃欖澕 鞚鸽鞚� Michael Y. Chi臧� 歆�雮� 3臧滌洈 霃欖晥 鞚措 69,802欤� 韥措灅鞀� A 欤检嫕鞚� 毵る弰頃橃棳 齑� 鞎� $427毵�鞚� 靾橃澋鞚� 鞓牳鞀惦媹雼�. 氚滍枆霅� 韥措灅鞀� A 欤检嫕鞚� 齑� 2鞏� 1,545毵� 欤�搿�, 瓿勴殟霅� 毵る弰電� 鞝勳泊 欤检嫕鞚� 氙鸽頃� 0.0001%鞐� 頃措嫻頃橂┌, 3臧滌洈 雸勳爜 毵る弰電� 鞎� 0.03%鞐� 雼暕雼堧嫟.
靹滊獏鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵�鞝曥爜 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頃橂┌, Rule 10b5-1鞐� 霐半澕 瓯半灅 瓿勴殟鞚� 欷�靾橂悩瓿� 鞛堨潓鞚� 氚濏灆雼堧嫟. 雼るジ 鞛 歆�響�, 鞝勲, 鞖挫榿 鞐呺嵃鞚错姼電� 鞝滉车霅橃 鞎婌晿鞙茧┌, 鞚措矆 鞝滌稖鞚� Rule 144鞐� 霐半ジ 鞝堨皑鞝� 瓿奠鞐� 攵堦臣頃╇媹雼�.
Hims & Hers Health, Inc. (HIMS) 鈥� D茅p么t du formulaire 144 r茅v猫le l鈥檌ntention d鈥檜n initi茅 de vendre 250 actions de Classe A (valeur marchande estim茅e 脿 16 110 $) 脿 partir du 1er ao没t 2025 via Fidelity Brokerage 脿 la NYSE. L鈥檃vis d茅taille 茅galement les activit茅s r茅centes de l鈥檌niti茅 : au cours des trois derniers mois, la m锚me personne, Michael Y. Chi, a d茅j脿 vendu 69 802 actions de Classe A pour un produit brut d鈥檈nviron 4,27 millions de $. Le nombre total d鈥檃ctions de Classe A en circulation est de 215,45 millions, ainsi la vente pr茅vue repr茅sente une part n茅gligeable de 0,0001 % des actions en circulation, tandis que les ventes cumul茅es sur trois mois s鈥櫭﹍猫vent 脿 environ 0,03 %.
Le signataire affirme ne pas avoir connaissance d鈥檌nformations d茅favorables non divulgu茅es et, s鈥檌l s鈥檃ppuie sur la r猫gle 10b5-1, qu鈥檜n plan de trading conforme est en place. Aucune autre donn茅e financi猫re, pr茅vision ou mise 脿 jour op茅rationnelle n鈥檈st fournie ; ce d茅p么t est strictement un avis proc茅dural conform茅ment 脿 la r猫gle 144.
Hims & Hers Health, Inc. (HIMS) 鈥� Form 144 Einreichung offenbart die Absicht eines Insiders, 250 Class A Aktien (gesch盲tzter Marktwert $16.110) ab dem 1. August 2025 眉ber Fidelity Brokerage an der NYSE zu verkaufen. Die Mitteilung enth盲lt zudem Details zu j眉ngsten Insideraktivit盲ten: In den vergangenen drei Monaten hat dieselbe Person, Michael Y. Chi, bereits 69.802 Class A Aktien verkauft und dabei Bruttoerl枚se von rund $4,27 Millionen erzielt. Die ausstehenden Class A Aktien belaufen sich auf insgesamt 215,45 Millionen, sodass der geplante Verkauf einen vernachl盲ssigbaren Anteil von 0,0001% der ausstehenden Aktien darstellt, w盲hrend die kumulierten Verk盲ufe der letzten drei Monate etwa 0,03% ausmachen.
Der Unterzeichner best盲tigt, dass ihm keine nicht offengelegten wesentlichen negativen Informationen bekannt sind und dass im Falle der Nutzung der Regel 10b5-1 ein konformer Handelsplan besteht. Es werden keine weiteren finanziellen Kennzahlen, Prognosen oder operative Updates bereitgestellt; die Einreichung ist ausschlie脽lich eine formale Mitteilung gem盲脽 Regel 144.
FAQ
How many HIMS shares does the insider plan to sell under this Form 144?
When is the planned sale date for the HIMS shares?
How much stock has the insider sold in the last three months?
What percentage of HIMS鈥檚 outstanding shares does the planned sale represent?
Does the filing indicate any undisclosed negative information about HIMS?
